GLP-1 insurance coverage in 2026: what gets covered, what gets denied
Roughly 40 percent of large employer commercial plans cover at least one GLP-1 for obesity in 2026. Medicare covers two indications (cardiovascular and sleep apnea) and one drug (Wegovy for CV, Zepbound for OSA). Medicaid is state-by-state, and most states cover only the diabetes brands. We walk through every coverage path, the prior authorization process step by step, the most common denial reasons, the four appeal pathways, and the templates we publish for every major payer.
The short version
Coverage breaks into three buckets. Commercial insurance is the most variable: roughly 40 percent of large employer plans cover at least one branded GLP-1 for obesity, the rest cover only the diabetes brands. The gate is prior authorization, which is denied about half the time on first submission and overturned about half the time on appeal. Medicare Part D covers Wegovy for cardiovascular indication and Zepbound for moderate-to-severe sleep apnea, neither for obesity alone. Medicaid is 15 states yes, 35 states no for obesity coverage; diabetes coverage is universal across states. HSA and FSA money is eligible for both branded and compounded GLP-1 with a prescription.
Key facts
| Coverage path | Typical out-of-pocket / mo | What unlocks it | Source |
|---|---|---|---|
| Commercial, obesity-covered plan | $25 to $100 copay | Approved PA + step therapy or comorbidity | KFF employer coverage survey |
| Commercial, T2D coverage | $25 to $80 copay | A1c above 6.5 + ICD-10 E11.x | ADA Standards of Care |
| Medicare Part D, Wegovy CV | $50 to $200 copay | Established CV disease + BMI 27+ | CMS Part D coverage |
| Medicare Part D, Zepbound OSA | $50 to $200 copay | AHI 15+ + BMI 30+ | FDA Zepbound OSA approval |
| Medicaid, T2D path | $0 to $8 copay | State formulary + PA | State-by-state breakdown |
| Medicaid, obesity path | $0 to $8 copay (15 states) | State formulary + PA | State-by-state breakdown |
| HSA / FSA, any path | Tax savings 25 to 40 percent | Prescription + receipts | IRS Pub 502 |
The KFF employer survey is the canonical reference for commercial coverage rates. We update the state Medicaid breakdown quarterly and on every major state PDL change.
How commercial insurance covers GLP-1
Commercial insurance in 2026 covers GLP-1 in one of three patterns: covered for obesity with prior authorization (the strongest case), covered for type 2 diabetes only, or excluded from the formulary entirely for obesity-indication brands. The KFF 2024 employer-coverage survey, updated in 2026, puts the obesity-covered share at roughly 40 percent of large employers (200+ employees), down from 49 percent in the 2024 survey. Small-employer plans cover GLP-1 for obesity at closer to 20 percent. Marketplace (Affordable Care Act) silver and gold plans cover at variable rates by issuer and state.
The single most important thing to check is your plan's formulary, not your insurer's general policy. UnitedHealthcare and OptumRx (its PBM) tightened obesity criteria in 2025 to require BMI 30 plus a comorbidity, six months of documented dietary intervention, and step therapy through phentermine or orlistat. Many UnitedHealthcare commercial plans cover Wegovy under those criteria. Some UnitedHealthcare employer plans carve out anti-obesity medications entirely. Both are common; both are technically "UnitedHealthcare." Always check the specific plan formulary. Templates for each major payer: Aetna, Cigna, UnitedHealthcare, Anthem BCBS, Blue Shield CA.
The prior authorization process, step by step
Prior authorization is the gate. Every commercial plan that covers GLP-1 for obesity requires it. The process has six steps and we walk through each one on the satellite article GLP-1 prior authorization step by step. In sequence: the prescriber submits the PA form with the supporting documentation (BMI, comorbidity ICD-10, lifestyle intervention notes, step therapy or contraindication); the insurer's PBM reviews against the policy criteria within 72 hours to 7 business days; the insurer returns approval, denial or request for additional information; if denied, the patient has 180 days to appeal.
Documentation makes or breaks the PA. The PA fails most often because of incomplete documentation, not because the patient does not qualify. The criteria we see most plans require, in approximate order of importance: BMI documented within the past 30 days with height and weight, comorbidity diagnosis with the correct ICD-10 code (E66.01 for morbid obesity, I10 for hypertension, E78.x for dyslipidemia, G47.33 for sleep apnea, E11.x for diabetes), six months of documented lifestyle intervention (dietitian notes, MyPlate tracker logs, or a structured program), prior anti-obesity medication trial or contraindication (phentermine, orlistat, naltrexone-bupropion, liraglutide), and a treatment plan with target weight loss and monitoring schedule.
Common denial reasons and how to overturn them
The denial-reason taxonomy is small and stable. Six categories cover roughly 90 percent of denials. We publish a template appeal letter for each: step therapy not met, BMI below threshold, no comorbidity documentation, no lifestyle intervention documented, formulary exclusion, and not medically necessary. Each template walks through the trial evidence and the policy citation that supports the appeal. The single most overturnable denial is step-therapy-not-met when the patient has a documented contraindication or intolerance to the step-therapy drug.
The four appeal pathways
The appeal process under the Affordable Care Act and ERISA gives the patient four sequential paths. We cover the strategic order in the satellite article four appeal paths after a GLP-1 denial.
- Peer-to-peer review. The prescriber requests a call with the insurer's medical director. Fast (often within 5 business days), informal, and frequently successful when the prescriber can frame the trial evidence in clinical terms. Roughly 30 to 50 percent of denials are overturned at peer-to-peer.
- First-level internal appeal. Written submission to the insurer, formal letter format, additional documentation as needed. Insurer must respond within 30 days (standard) or 72 hours (expedited). About 30 to 40 percent of denials are overturned here.
- External review by an Independent Review Organization. Mandatory under the ACA for denials of medical necessity or experimental treatment claims. The IRO is independent of the insurer and free to the patient. Decisions are binding on the insurer. About 40 to 50 percent of GLP-1 external reviews overturn the denial.
- State insurance commissioner complaint. The state regulator can investigate denials that appear to violate state insurance law. Slower path, lower overturn rate, but useful when the denial appears to apply a criterion not in the published policy.
Medicaid coverage state by state
Medicaid coverage is the most variable piece of GLP-1 coverage. Federal Medicaid policy permits states to cover anti-obesity medications but does not require it. As of 2026, approximately 15 state Medicaid programs cover Wegovy or Zepbound for obesity with prior authorization; 35 states cover only the diabetes brands (Ozempic, Mounjaro) for patients with type 2 diabetes. California Medi-Cal removed obesity-indication GLP-1 from its preferred drug list in mid-2025; Massachusetts and Pennsylvania expanded coverage in the same year. State-specific PA criteria, formulary status and PA submission contact for every state lives at Medicaid GLP-1 coverage by state and the deeper analysis at Medicaid GLP-1 coverage explainer. The Medicaid managed care PA pathway has additional steps; see best programs for Medicaid patients for the practical guide.
Medicare Part D coverage
Medicare Part D, under the 2003 Medicare Modernization Act, excludes drugs for weight loss from coverage. That exclusion still stands. Two indication-specific exceptions opened up in 2024 and they materially change coverage for older patients. Wegovy carries a Part D-eligible indication for cardiovascular risk reduction in adults with established cardiovascular disease and BMI 27 or above, following the SELECT trial published in NEJM in November 2023; the FDA labeled it in March 2024. Zepbound carries a Part D-eligible indication for moderate-to-severe obstructive sleep apnea in adults with obesity, following SURMOUNT-OSA; the FDA labeled it in December 2024. See FDA on Wegovy CV approval and FDA on Zepbound OSA approval. The two indications open coverage for the senior population that previously had no Part D path. Practical implementation is covered in Wegovy CV coverage and Wegovy and Zepbound OSA coverage.
Medicare Advantage plans can layer additional benefits beyond Part D and a small number of MA plans cover anti-obesity medications as a supplemental benefit. The CMS-published list of MA plans with anti-obesity coverage is updated annually; see our senior-focused overview for the navigation.
Employer-sponsored plans and self-funded carve-outs
Employer-sponsored health plans are where most working-age US patients get GLP-1 coverage. Two structural patterns matter. Fully-insured plans use the insurer's standard formulary; if Aetna covers Wegovy on its commercial formulary, an Aetna fully-insured employer plan covers Wegovy. Self-funded plans (the employer bears the claim cost; the insurer is administering claims) often carve out anti-obesity medications entirely as a cost-control measure. The carve-out is visible on the plan's summary plan description (SPD) and on the formulary. If the SPD lists anti-obesity medications as "not covered," PA is futile; the appeal path runs through the employer benefits committee, not the insurer.
HSA, FSA and HRA
HSA, FSA and HRA accounts are eligible payment sources for GLP-1 with a prescription, under IRS Publication 502. This applies to both branded and compounded medication, and to the membership fee at a licensed telehealth program. The tax savings are real: a $400 a month cash-pay program paid from an HSA in the 24 percent federal bracket plus 5 percent state plus FICA savings is about 33 percent cheaper than the same program paid from after-tax dollars. The HSA path is the single biggest cost-reducer for cash-pay patients who have access to a high-deductible health plan and an HSA. Walk-through in HSA and FSA for GLP-1.
When your insurance changes
Plan changes (open enrollment, job change, ACA marketplace re-enrollment) introduce coverage discontinuity risk. The continuity-of-care path lets a patient on a stable GLP-1 dose under the prior plan request a short-term coverage bridge under the new plan, typically 60 to 90 days, while a new PA is processed. Submit the request with the prior PA approval letter and a clinical note documenting current dose and response. Where the new plan does not cover GLP-1 at all, the bridge buys time to set up either a cash-pay path or a manufacturer-direct cash program. See when your insurance changes for the playbook.
Payer-specific PA templates
We publish PA letter templates for the ten largest US payers, with payer-specific policy citations and submission instructions. Each template walks through the documentation checklist, the criteria the payer evaluates, and the language we have seen overturn denials. The full library is at PA letter templates and the by-PBM index is at PA letters by PBM. The five highest-traffic templates are Aetna, Cigna, UnitedHealthcare, Anthem BCBS and Blue Shield CA. The condition-specific framing matters: a PA for T2D goes to the diabetes-brand criteria (Ozempic, Mounjaro), a PA for obesity goes to the obesity-brand criteria (Wegovy, Zepbound), and a PA for CV risk reduction goes to the SELECT language. We cover each path in the per-letter pages.
How insurers actually decide
Insurers do not evaluate PA requests by reading the medical record from the top. The PBM clinical reviewer (often a PharmD or RN) runs the submission against a checklist generated from the insurer's policy bulletin. If every box is checked, approval. If a box is unchecked, the reviewer escalates to medical director review or denies. The single most useful framing for patients and prescribers is to think of the PA as a criteria-checklist match, not a narrative argument. The narrative belongs in the appeal letter; the PA itself is documentation. See how insurance decides GLP-1 approval for the operational walk-through.
Off-label and uncovered indications
GLP-1 prescribed for PCOS, NAFLD or alcohol use disorder is off-label in 2026 and almost universally denied by commercial insurance for that indication. The standard path is to pivot to a covered indication the patient also qualifies for (obesity with comorbidity, T2D, CV risk reduction) and prescribe under that label. PCOS-specific PA strategy is in PCOS and GLP-1 and PCOS with metabolic syndrome. NAFLD strategy is in Zepbound and MASH and MASH MASLD. Alcohol use disorder is in semaglutide and AUD; off-label and no current insurance path.
Trial evidence and policy citations
The trial evidence base PA letters cite, in order of frequency: STEP-1 (Wegovy, NEJM 2021) for the obesity indication, SURMOUNT-1 (Zepbound, NEJM 2022) for the obesity indication, SELECT (Wegovy, published in NEJM 2023) for the cardiovascular risk reduction indication, SURMOUNT-OSA (Zepbound, NEJM 2024) for the OSA indication, FLOW (Ozempic, NEJM 2024) for the renal indication, SURPASS (tirzepatide for T2D, multiple NEJM and Lancet publications 2022 to 2023). We cite the specific paper and the relevant outcome on every PA letter and on the deep-dive trial pages. The federal external-review process is documented at healthcare.gov external review, and ERISA-plan appeal rules at the Department of Labor EBSA. The full SELECT analysis is in SELECT MACE deep dive. The full SURMOUNT-OSA picture is in Zepbound OSA.
What to do next
If you have commercial coverage and no PA submitted yet, start with the payer-specific template for your insurer at PA templates and the prior-auth walkthrough at PA step by step. If you have been denied, match your denial reason to the appropriate appeal template and start with peer-to-peer review. If you are on Medicare, the path is indication-dependent: Wegovy CV or Zepbound OSA. If you are on Medicaid, start at your state's page. If your plan does not cover GLP-1 and you need a cash-pay path now, head to the cost pillar and the cheapest legitimate programs.
